<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093223</url>
  </required_header>
  <id_info>
    <org_study_id>CVR001</org_study_id>
    <nct_id>NCT00093223</nct_id>
  </id_info>
  <brief_title>A Safety Study of ABI-007 for In-Stent Restenosis</brief_title>
  <official_title>A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will treat patients with a new chemotherapeutic medicine who have undergone a&#xD;
      successful and uncomplicated de novo stent placement in up to two native coronary arteries.&#xD;
      The purpose of the trial is to determine the appropriate dose of the new medicine for future&#xD;
      trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse&#xD;
      events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See inclusion/exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2001</start_date>
  <completion_date type="Actual">December 1, 2007</completion_date>
  <primary_completion_date type="Actual">December 1, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events and serious adverse events.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events at 2 months following the stent procedure.</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability for ABI-007</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of restenosis at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35mg/m^2 infusion time is 3.5 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of 35mg.m^2 with the second dose given 2 months later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Nanoparticle Albumin Bound</intervention_name>
    <description>Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Nanoparticle Albumin Bound</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Nanoparticle Albumin Bound</intervention_name>
    <description>35mg/35 infusion time is 3.5 minutes</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergone a successful and uncomplicated de novo stent placement in up to two native&#xD;
             coronary arteries&#xD;
&#xD;
          -  Diagnosis of angina pectoris&#xD;
&#xD;
          -  At least 18 yrs old&#xD;
&#xD;
          -  If female, negative pregnancy test, non-lactating, and agree to utilize methods to&#xD;
             prevent pregnancy&#xD;
&#xD;
          -  No previous treatment for In-Stent Restenosis&#xD;
&#xD;
          -  Patient agrees to comply with follow-up evaluation&#xD;
&#xD;
          -  Informed Consent obtained&#xD;
&#xD;
          -  Target vessel at least 3 mm diameter&#xD;
&#xD;
          -  Total stent less than 25 mm&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 30%&#xD;
&#xD;
          -  No more than a single stent will be used per lesion&#xD;
&#xD;
          -  No more than one stented lesion per vessel with the exception that 2 lesions in a&#xD;
             single vessel are allowable if covered by less than 25 mm of continuous stent&#xD;
&#xD;
          -  By Intravascular Ultrasound (IVUS), stent is fully opposed and has a minimum diameter&#xD;
             of 3 mm or an in-stent luminal area of at least 7 mm2&#xD;
&#xD;
          -  TIMI 3 coronary flow post-stenting&#xD;
&#xD;
          -  No angiographic evidence of thrombus post-stenting&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  More than two lesions treated with Percutaneous Coronary Intervention (PCI) or it is&#xD;
             anticipated that additional lesions will require treatment within two months&#xD;
&#xD;
          -  Previous PCI within preceding three months&#xD;
&#xD;
          -  Previous participation in another study within 30 days&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Factors making follow-up difficult&#xD;
&#xD;
          -  Intended surgical intervention within 6 months of study participation&#xD;
&#xD;
          -  Investigator decision that patient is unsuitable&#xD;
&#xD;
          -  Recipient of heart transplant&#xD;
&#xD;
          -  Q wave or non-Q wave Myocardial Infarction (MI) with documented total CK greater than&#xD;
             2X normal upper limits within the preceding 24 hrs and the CK and CK-MB enzymes remain&#xD;
             above normal at the time of the procedure&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  May refuse blood transfusion&#xD;
&#xD;
          -  Gastro-intestinal bleeding within past 3 months&#xD;
&#xD;
          -  Platelet count less than 100,000 cells/mm3&#xD;
&#xD;
          -  Impaired renal function&#xD;
&#xD;
          -  Known allergies/hypersensitivity to aspirin, clopidogrel bisulfate, and/or stainless&#xD;
             steel&#xD;
&#xD;
        Exclusion Criteria Related to Angioplasty:&#xD;
&#xD;
          -  Intervention for another lesion occurred within 90 days or is planned for within 60&#xD;
             days after the index procedure&#xD;
&#xD;
          -  Stent is located in a coronary bypass&#xD;
&#xD;
          -  Unprotected left main disease with greater than 50% stenosis&#xD;
&#xD;
          -  Lost a side branch greater than 2 mm during stenting procedure&#xD;
&#xD;
          -  Angiographic evidence of thrombus post-stenting&#xD;
&#xD;
          -  Prior stent within 5 mm of target lesion&#xD;
&#xD;
          -  Left ventricular ejection fraction less than 30%&#xD;
&#xD;
          -  Greater than 50% stenosis proximal or distal to target lesion&#xD;
&#xD;
          -  Malposition, dissection, or unmasking of a significant narrowing in the inflow or&#xD;
             outflow area of the implanted stent&#xD;
&#xD;
          -  Patient has received a drug coated stent as part of this procedure&#xD;
&#xD;
        Exclusion Criteria Related to ABI-007:&#xD;
&#xD;
          -  Absolute neutrophil count is less than 1500 cells/mm3&#xD;
&#xD;
          -  Platelet count is less than 100,000 cells/mm3&#xD;
&#xD;
          -  Bilirubin greater than 1.5 mg/dl or SGOT and SGPT greater than 2.5X upper limit of&#xD;
             normal or alkaline phosphatase greater than 2.5X upper limit of normal&#xD;
&#xD;
          -  Creatinine greater than 2.5X upper limit normal&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy of NCI toxicity Criteria Scale of Grade greater&#xD;
             than 1&#xD;
&#xD;
          -  Immunosuppressed or has HIV or AIDS&#xD;
&#xD;
          -  Hypersensitivity to Taxane&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos√© Iglesias, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abraxis BioScience, Inc.</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 4, 2004</study_first_submitted>
  <study_first_submitted_qc>October 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2004</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In-Stent Restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

